Skip to main content
OpenTrials
Completed

NCT Number: NCT03286140

Early Venous Reflux Ablation Ulcer Trial

The EVRA study evaluates the effects of early endovenous ablation on ulcer healing in patients with chronic venous ulceration. Half the patients are randomised to receive early endovenous ablation (within 2 weeks) and half to standard care

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Imperial College London

London, W68RF, United Kingdom

About this study

A large number of patients (around 1% of the adult population) suffer from an ulcer (break in the skin surface) near the ankle. In most people, such an injury should heal up within a week or two. However, when there is an underlying problem with the skin, ulcers do not heal and may result in longstanding (chronic), painful, smelly and embarrassing wounds. The ulcers are often due to varicose veins in the legs, which can cause skin breakdown and ulcer formation. To get the ulcer to heal, the current best treatment is to wear a tight compression bandage with multiple layers, with which about 60% of these ulcers will heal within 24 weeks. There is evidence that treatment of the varicose veins by surgery will prevent the ulcer from returning after it has healed. Recent studies have suggested that newer techniques of treating varicose veins, such as injecting a medicine into the varicose vein (sclerotherapy) or treating the vein with heat ablation to seal it (using laser or radiofrequency), in an outpatient setting may help the ulcers to heal more quickly and (like surgery) reduce the chance of the ulcer coming back. These techniques can be carried out in the outpatient setting and are much better tolerated by patients in comparison to surgery. The aim of this study is to see whether early treatment of varicose veins using sclerotherapy or heat ablation helps with healing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current leg ulceration of greater than 6 weeks, but less than 6 months duration
  • Able to give informed consent to participate in the study after reading the patient information documentation
  • Patient age > 18 years
  • Ankle Brachial Pressure Index (ABPI) ≥ 0.8
  • Superficial venous disease on colour duplex assessment deemed to be significant enough to warrant ablation by the treating clinician (either primary or recurrent venous reflux)

Exclusion criteria

  • Presence of deep venous occlusive disease or other conditions precluding superficial venous intervention (at the discretion of local research team)
  • Patients who are unable to tolerate any multilayer compression bandaging / stockings will be excluded. However, concordance with compression therapy can be variable for patients at different times. Patients who are generally compliant with compression, but unable to tolerate the bandages for short periods will still be eligible to inclusion. A period of non-compliance with compression bandages will not be considered a protocol violation, but a normal variation within the spectrum of 'standard therapy'.
  • Inability of the patient to receive prompt endovenous intervention by recruiting centre
  • Pregnancy (female participants of reproductive age will be eligible for inclusion in the study, subject to a negative pregnancy test prior to randomisation)
  • Leg ulcer of non-venous aetiology (as assessed by responsible clinician)
  • Patient deemed to require skin grafting

Treatment and study plan

Early endovenous ablation

Procedure

Delayed endovenous intervention

Procedure

Primary outcomes

  1. Time to Ulcer Healing From Date of Randomisation to Date of Healing up to 365 Days

    Time frame: time from date of randomisation to date of healing up to 365 days

    For the purposes of this study, ulcer healing is defined as complete re-epithelialisation of all ulceration on the randomised (reference) leg in the absence of a scab (eschar) with no dressing required.

Secondary outcomes

  1. Percentage of Participants With Ulcer Healing

    Time frame: 24 weeks & time to ulcer healing up to 365 days

    Healing rate will be reported at 24 weeks using the percentage of participants with a healed ulcer

  2. Ulcer Recurrence / Ulcer Free Time

    Time frame: Up to 12 months (and with the extension, up to 5 years (median approximately 3.7 years))

    Will be calculated up to 1 year for each study arm and with the extension, up to 5 years (median approximately 3.7 years). This will allow a very practical and easily understood assessment of the clinical difference between the 2 arms of the study. This will also allow comparison with other studies that have reported this outcome. In order to facilitate accurate calculation of reoccurrence / ulcer free time, clinical follow up will be continued after ulcer healing up to 1 year after randomisation.

  3. Quality Of Life Questionnaire up to 365 Days

    Time frame: 6 weeks post randomisation, 6 months, 12 months

    Disease specific (AVVQ) quality of life

    The Aberdeen Varicose Vein Questionnaire (AVVQ) is a validated patient-reported disease-specific health questionnaire to assess quality of life in patients with varicose veins. The AVVQ comprises a diagram on which patients draw on their varicose veins and a questionnaire with 12 questions, half of which require a response for each leg. The scores range from 0 to 100 (no effect to severe effect).

  4. Generic (SF-36) Quality of Life Assessment

    Time frame: 6 weeks post randomisation, 6 months, 12 months

    Generic (SF-36) quality of life assessment

    The Short Form questionnaire-36 items (SF-36) is a generic quality-of-life tool used to determine people's physical and mental health. It has been validated in many patient groups, including those with varicose veins. The physical domain measures physical functioning, physical role limitations, body pain and general health, whereas the mental dimension measures vitality, social functioning, mental health role limitations and general mental health. Two separate scores are produced (separate physical/mental component summary scores), in addition to the eight separate domain scores. Each score is measured on a scale of 0 to 100 (worst to best). Scores represent the percentage of total possible score achieved.

  5. EuroQol-5 Dimensions (EQ-5D)

    Time frame: 6 weeks post randomisation, 6 months, 12 months

    The EuroQol-5 Dimensions (EQ-5D) is a widely recognised, generic tool to measure health outcomes and has been validated in a variety of patient groups, including those with venous leg ulcers. The EQ-5D questionnaire comprises two sections; the first assesses the participant's mobility, self-care, ability to perform usual activities, pain/discomfort and anxiety/depression levels, and the second records the participant's self-rated health on a vertical score of 0 to 100.

  6. Health Economic Assessment

    Time frame: Baseline, 6 weeks, 6 months, 12 months

    A within-RCT cost effectiveness analysis will be carried out based on the data collected in the trial, Resource use items in hospital and community care related to the treatment of venous ulceration or complications will be recorded for each patient at each follow-up. Resource use will be multiplied by UK unit costs obtained from published literature, HRG costs, and manufacturers' list prices to calculate overall costs. A standard tariff will be applied for each bandage change. Utilities (QALYs) will be calculated from the EQ-5D questionnaire administered to patients

  7. Clinical Success - Presence of Residual / Recurrent Reflux in the Veins

    Time frame: at 6 weeks

    The presence of residual / recurrent varicose veins remaining on the venous duplex. Any reflux detected by the vascular scientists (as per local scanning policies) is recorded as presence of residual reflux and therefore considered incomplete clinical success. No presence of residual reflux is considered clinical success. (Clinical-Etiology-Anatomy-Pathophysiology) ranges from C0 which means absolutely no venous disease that can be seen or felt in the legs to C6 which means an open and active venous leg ulcer. For this outcome measure: Healed venous leg ulcer (C5), Active venous leg ulcer (C6).

  8. Clinical Success - VCSS

    Time frame: at 6 weeks

    The Venous Clinical Severity Score (VCSS) is a component of the Venous Severity Scoring System designed in 2000 by an ad hoc American Venous Forum committee consensus, in order to compliment the CEAP classification and quantify the severity of disease and subsequent improvement or decline. The VCSS has 10 components (pain, varicose veins, venous oedema, skin pigmentation, inflammation, induration, compression used and active ulcer, duration, number and size), each with four categories assigned values of 0-3. The overall scores can range from 0 (lowest severity) to 30 (highest severity).

  9. Clinical Success - Complications

    Time frame: up to 12 months

    Number of complications related to the endovenous intervention

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

  • Universidad de Granada
  • University of Birmingham
  • University of Manchester
  • University of Warwick

Registry information

Official study title

A Randomised Clinical Trial to Compare Early Versus Delayed Endovenous Treatment of Superficial Venous Reflux in Patients With Chronic Venous Ulceration

Acronym: EVRA

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Sep 18, 2017
Registry last updated
May 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.